Administration of BNT162b2 mRNA COVID-19 vaccine to subjects with various allergic backgrounds.
COVID- 19
anaphylaxis
drug allergy
polyethylene glycol
vaccination
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
02
2023
accepted:
31
07
2023
medline:
1
9
2023
pubmed:
1
9
2023
entrez:
1
9
2023
Statut:
epublish
Résumé
The mRNA-based COVID-19 vaccine was introduced to the general public in December 2020. Shortly thereafter, safety concerns were raised due to the reporting of allergic reactions. Allergy-related disorders were suspected to be significant risk factors and the excipient polyethylene glycol was suggested to be a robust allergen. This is a retrospective study analysis. Subjects with putative risk factors for severe allergic reactions to the Pfizer-BioNTech BNT162b2 vaccine were referred for vaccination under observation at the Unit of Allergy and Clinical Immunology. Data was collected for each subject, including demographic details, medical history and previous reactions to any allergen. When appropriate, skin tests were done prior to vaccination. A total of 346 subjects received 623 vaccine doses under observation. The study included patients with various allergy-related disorders (n=290) and those with allergy to a previous COVID-19 vaccine dose (n=56). Both groups showed female predominance (78% and 88%, p=NS). Patients without reactions to previous doses reported more drug allergy (80% vs. 39%, p<0.001) and previous anaphylaxis (64% vs. 14%, p<0.001). There was no difference in sensitivity to other allergens, including polyethylene glycol. Under observation, mild allergic reactions were noted in 13 individuals characterized by female gender (100%), a history of anaphylaxis (69%) and drug allergy (62%). In 7 subjects, allergy was treated with antihistamines while others recovered spontaneously. Our study demonstrates that vaccination under specialist-supervision is a powerful tool for reducing over-diagnosis of systemic reactions and for rapid and reliable collection of vaccine safety data.
Sections du résumé
Background
UNASSIGNED
The mRNA-based COVID-19 vaccine was introduced to the general public in December 2020. Shortly thereafter, safety concerns were raised due to the reporting of allergic reactions. Allergy-related disorders were suspected to be significant risk factors and the excipient polyethylene glycol was suggested to be a robust allergen.
Methods
UNASSIGNED
This is a retrospective study analysis. Subjects with putative risk factors for severe allergic reactions to the Pfizer-BioNTech BNT162b2 vaccine were referred for vaccination under observation at the Unit of Allergy and Clinical Immunology. Data was collected for each subject, including demographic details, medical history and previous reactions to any allergen. When appropriate, skin tests were done prior to vaccination.
Results
UNASSIGNED
A total of 346 subjects received 623 vaccine doses under observation. The study included patients with various allergy-related disorders (n=290) and those with allergy to a previous COVID-19 vaccine dose (n=56). Both groups showed female predominance (78% and 88%, p=NS). Patients without reactions to previous doses reported more drug allergy (80% vs. 39%, p<0.001) and previous anaphylaxis (64% vs. 14%, p<0.001). There was no difference in sensitivity to other allergens, including polyethylene glycol. Under observation, mild allergic reactions were noted in 13 individuals characterized by female gender (100%), a history of anaphylaxis (69%) and drug allergy (62%). In 7 subjects, allergy was treated with antihistamines while others recovered spontaneously.
Conclusion
UNASSIGNED
Our study demonstrates that vaccination under specialist-supervision is a powerful tool for reducing over-diagnosis of systemic reactions and for rapid and reliable collection of vaccine safety data.
Identifiants
pubmed: 37654487
doi: 10.3389/fimmu.2023.1172896
pmc: PMC10465362
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1172896Informations de copyright
Copyright © 2023 Ribak, Rubin, Talmon, Dranitzki, Shamriz, Hershkowitz, Tal and Hershko.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Allergy. 2021 Nov;76(11):3538-3540
pubmed: 34370884
Science. 2021 Jan 1;371(6524):10-11
pubmed: 33384356
J Allergy Clin Immunol. 2018 Feb;141(2):463-472
pubmed: 29413255
World Allergy Organ J. 2021 Feb;14(2):100517
pubmed: 33558825
Allergy. 2021 Jun;76(6):1617-1618
pubmed: 33320974
J Allergy Clin Immunol Pract. 2021 Feb;9(2):670-675
pubmed: 33011299
Clin Exp Allergy. 2021 Jun;51(6):770-777
pubmed: 33813758
J Control Release. 2023 Feb;354:316-322
pubmed: 36549393
J Allergy Clin Immunol Pract. 2022 Nov;10(11):2969-2976
pubmed: 35872216
Vaccines (Basel). 2021 Jan 11;9(1):
pubmed: 33440794
J Allergy Clin Immunol Pract. 2021 Apr;9(4):1423-1437
pubmed: 33388478
JAMA. 2021 Apr 20;325(15):1562-1565
pubmed: 33683290